Monte Rosa Therapeutics
GLUE
68 hedge funds and large institutions have $272M invested in Monte Rosa Therapeutics in 2023 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 33 increasing their positions, 10 reducing their positions, and 10 closing their positions.
230% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 10
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.08% less ownership
Funds ownership: 80.57% → 80.49% (-0.08%)
1% less funds holding
Funds holding: 69 → 68 (-1)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
12% less capital invested
Capital invested by funds: $310M → $272M (-$37.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$17.1M |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
+$2.64M |
| 3 |
BlackRock
New York
|
+$1.62M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$1.36M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$22.5M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$11M |
| 3 |
Millennium Management
New York
|
-$912K |
| 4 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$157K |
| 5 |
Squarepoint
New York
|
-$109K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Ameriprise
Minneapolis,
Minnesota
| – | -$85.3K | -10,955 | Closed |
|
77
Two Sigma Investments
New York
| – | -$78.7K | -10,100 | Closed |
|
78
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$17K | -2,190 | Closed |
|
GLUE Hedge Fund Activity: Q2 2023 in Review
68 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q2 2023, worth a combined $272M — down 12% from $310M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of GLUE and 9 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 33 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $17.1M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $22.5M sold.
- 68 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q2 2023, down from 69 in Q1 2023.
- Funds reported $272M of Monte Rosa Therapeutics stock for Q2 2023, down 12% quarter-over-quarter.
- 9 funds opened new Monte Rosa Therapeutics positions in Q2 2023 and 10 closed out, a net change of -1 holder.
- The largest Monte Rosa Therapeutics buyer in Q2 2023 was Baker Bros. Advisors, an estimated $17.1M added.
- The largest Monte Rosa Therapeutics seller in Q2 2023 was Cormorant Asset Management, an estimated $22.5M sold.
Based on aggregated 13F filings for Q2 2023.